Yesterday the Food and Drug Administration approved Januvia (sitagliptin phosphate) manufactured by Merck & Co. for treatment of type 2 diabetes.
Januvia is a new drug for diabetes treatment called a DPP-4 inhibitor and can be used alone or in combination with other oral diabetes medications when exercise and diet do not control the disease.
According to the FDA news release and Merck's press release, type 2 diabetes affects more than 20 million Americans. Diabetes is linked to many serious health problems such as heart disease, kidney disease and blindness.
Pill Identification - JANUVIA
100 mg tablets are beige, round, film-coated tablets with 277 on one side
50 mg tablets are light beige, round, film-coated tablets with 112 on one side
25 mg tablets are pink, round, film-coated tablets with 221 on one side
For more information, please see the Januvia website.